Assessment of Bacterial Co-Infection and Antibiotic Prescribing in Patients with COVID-19

This work presents a comprehensive analysis of bacterial coinfections and antibiotic application patterns among COVID-19 cases. A systematic review was conducted to identify applicable studies published between 2020 and 2022. Studies reporting on bacterial isolates from COVID-19 cases were included, and data on the frequency of bacterial coinfections and antimicrobial patterns were analyzed.  The results revealed a high frequency of bacterial coinfections among COVID-19 cases, with varying probabilities across different subsets. Out of 317668 COVID-19 cases,5.11 were linked as having bacterial co-infections. still, in some studiеs89.68 had bacterial co-infections. These findings emphasize the significance of considering bacterial coinfections in the operation of COVID-19 cases, as they can impact complaint inflexibility and case issues.  The analysis also linked colorful bacterial isolates associated with COVID-19 cases. The most current bacterial insulate was Escherichia coli (E. coli), followed by Klebsiella pneumoniae and Staphylococcus aureus. The presence of different bacterial species underscores the complexity of co-infections observed among the subjects, furnishing precious perceptivity into the microbial geography associated with COVID-19.  likewise, the study examined the application patterns of different antibiotics. Piperacillin was the most constantly used antibiotic, followed by Azithromycin, Ceftriaxone, and Meropenem. These findings punctuate the significance of antibiotics in healthcare and their wide use in treating colorful infections. Certain antibiotics demonstrated advanced application rates, suggesting their significant part in clinical practice, while others represented a lower proportion of the total count.  Overall, this comprehensive analysis provides precious perceptivity into the frequency of bacterial coinfections and antibiotic application among COVID-19 cases.